Commercial pharmacogenetic-based decision-support tools in psychiatry
Chad A Bousman, Malcolm Hopwood
LANCET PSYCHIATRY | ELSEVIER SCI LTD | Published : 2016
Despite a compendium of pharmacotherapies available for treating psychiatric illnesses, suboptimal response to these therapies is typical and thought to be in part a result of genetic variation. This notion has sparked a personalised psychiatry movement, which has in turn led to the development of several commercial pharmacogenetic-based decision support tools marketed to psychiatrists as an alternative to typical, trial-and-error, prescribing. However, there is considerable uncertainty about the validity and usefulness of these tools and whether there is sufficient evidence to support their adoption. In this Personal View, we provide an introduction to these tools and assess their potential..View full abstract
CAB was supported by a University of Melbourne, Ronald Phillip Griffith Fellowship. This funding source had no involvement in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.